Skip to main content
Article thumbnail
Location of Repository

The study of molecular markers for the progression of Barrett's Oesophagus to adenocarcinoma to identify markers that can be used as diagnostic tools.

By Verity Anne Cadd


Barrett's oesophagus is a complication of gastro-oesophageal reflux disease and is the single most important predisposing factor for the development of adenocarcinoma of the oesophagus. New molecular markers are needed for early diagnosis and to monitor disease progression. Telomerase is a ribonuclear protein with reverse transcriptase activity, which uses its own RNA component as a template for the addition of telomeric repeats to the end of chromosomes. Telomerase activity has been studied during the neoplastic progression of Barrett's oesophagus using a TRAP based ELISA technique, which found telomerase to be reactivated early during . disease progression. A non-isotopic method of in situ hybridisation for the detection of the RNA component of telomerase has also been successfully developed. Plasminogen activation is an inducible extracellular proteolytic system involved in the regulation of cellular interactions and invasion. The components of the urokinase-type Plasminogen Activator system have been fully investigated during the progression of Barrett's oesophagus to adenocarcinoma utilising immunohistochemistry and ELISA techniques. Changes in the expression of this invasive phenotype were found to occur late during disease progression in malignant tissues. Two-oesophageal cell-lines have been characterised using molecular biological techniques to detect a range of molecular markers to produce ex vivo models of oesophageal adenocarcinoma and oesophageal squamous cell carcinoma. In order to assess the effects of bile salts and acidity on oesophageal tissues these celllines were then utilised as ex vivo models. Exposure to acidic conditions both alone and with bile salts altered the morphological appearance of the cells and disrupted adhesion molecules in the cellular membrane. Investigations into both telomerase reactivation and the plasminogen activator system have provided new information concerning the nature and timing of molecular changes during the Barrett's metaplasia/dysplasia/ adenocarcinoma sequence

Publisher: Cranfield University
Year: 2002
OAI identifier:
Provided by: Cranfield CERES

Suggested articles


  1. (1995). 81 Abstract Supplement 2 Hewin
  2. (1998). A novel amplicon at 8p22-23 results in over expression of cathepsin B in esophageal adenocarcinoma. doi
  3. (1995). A systematic review of the association between Barrett's esophagus and colon neoplasms. doi
  4. (1991). Abnormal expression of growth regulatory factors in Barrett's oesophagus. doi
  5. (1995). Absence of c-Ki-ras gene mutation in malignant and premalignant Barrett's oesophagus. doi
  6. (1995). Accumulation of genetic abnormalities during neoplastic progression in Barrett's esophagus. doi
  7. (1995). Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. doi
  8. Adenocarcinoma of the oesophagus and ectopic gastric mucosa. doi
  9. (1998). Altered cadherin and catenin complexes in the barrett's esophagusdysplasia-adenocarcinoma sequence Correlation with disease progression and dedifferentiation.
  10. and Kruse TJL 199 1. Assignment of the gene for urokinase-type plasminogen activator receptor to chromosome 19q13.
  11. and Virtanen 1.0.1996. Cytokeratin profile suggests mataplastic epithelial transformation in Barrett's oesophagus. doi
  12. (1998). Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. doi
  13. (1997). APC gene alterations in Barrett's metaplasia are implicated at an early stage in the carcinomgenesis of esophageal adenocarcinoma.
  14. (1999). Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesphagus: A comparative study. doi
  15. (1999). Applications of telomerase research in the fight against cancer. doi
  16. (1983). Barrett's esophagus comparison of benign and malignant cases. doi
  17. (1985). Barrett's esophagus in childhood. doi
  18. (1984). Barrett's esophagus in children: a consequence of chronic gastroesophageal reflux. doi
  19. (1994). Barrett's esophagus, Dysplasia and Adenocarcinoma. doi
  20. (1998). Barrett's esophagus, markers to distinguish risk groups.
  21. (1992). Barrett's Esophagus: Age, Prevalence, and extent of columnar epithelium.
  22. (1992). Barrett's esophagus: An acquired condition with genetic predisposition.
  23. (1993). Barrett's esophagus: New definitions and approaches in'children.
  24. (1993). Barrett's esophagus: Pathogenesis, epidemiology, functional abnormalities, malignant degeneration, and surgical management. doi
  25. (1986). Barrett's esophagus. doi
  26. (1987). Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease.
  27. (1997). Barrett's Esophagus. Current Opinion in Gastroenterology 13: doi
  28. (1991). Barrett's esophagus. Natural history, Incidence, Etiology and Complications. doi
  29. (1985). Barrett's oesophagus and colonic tumours. doi
  30. (1998). Barrett's oesophagus: Nficrosatellite analysis provides evidence to support the proposed metaplasia-dysplasia-carcinoma sequence. doi
  31. (1998). Bile Acid concentrations in the refluxate of patients with reflux oesophagitis. doi
  32. (1997). Bile in the oesophagus: clinical relevance and ambulatory detection. doi
  33. (1997). Bile reflux in columnar lined esophagus. doi
  34. (1992). Bile Salts do not modify the effects of pepsin in the fine structure of human oesophageal epithelium. Australian and New Zealand doi
  35. (2000). Bile Salts induce or blunt cell proliferation in Barrett's esophagus in an acid dependent fashion. doi
  36. (1996). Biologic characteristics of esophageal epithelial dysplasia assessed by proliferating cell nuclear antigen. doi
  37. (1995). Biological and clinical aspects of plasminogen activator inhibitor type 2.
  38. (1993). Biology and biochemistry of proteases in tumour invasion.
  39. (1997). Biomarkers for malignancy in the columnar-lined esophagus. doi
  40. (1989). Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. doi
  41. (1986). cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. doi
  42. (1991). Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. doi
  43. (2000). Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. doi
  44. (1997). Cellular localization of urokinase-type plasminogen activator, its inhibitors and their mRNAs in breast cancer tissues. doi
  45. (1950). Chronic peptic ulcer of the oesophagus and "oesophagitis".
  46. (1994). Classification and localisation of carcinoembryonic antigen (CEA) related antigen expression in normal oesophageal mucosa and squamous carcinoma. doi
  47. (2001). Clinical implications of telomerase detection. doi
  48. (1998). clinical pathology: Molecular Pathology 48: M198-M199 Lagorce-Pages doi
  49. (1999). Clinical significance of telomerase activity in the non-cancerous epithelial region of oesophageal squamous cell carcinoma. doi
  50. (1988). Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. doi
  51. (1997). Co-morbidities in childhood Barrett's esophagus. doi
  52. Composition of gastro-oesophageal refluxate. doi
  53. (1980). Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
  54. (1995). Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. doi
  55. (2000). Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. doi
  56. (1999). Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach. doi
  57. (1999). Differential expression of mucins and trefoil peptides in native epithelium, Barrett's metaplasia. and squamous cell carcinoma of the oesophagus. doi
  58. (1997). Distribution of cytokeratin markers in Barrett's specialised columnar epithelium. doi
  59. (1994). Dysplasia and aneuploidy as markers of malignant degeneration in Barrett's oesophagus. The Rotterdam Oesophageal Tumour Study Group. doi
  60. (1999). Dysplastic gastroesophageal junction nodules-A precursor to junctional adenocarcinoma. doi
  61. (1995). E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: An immunohistochemical. and immunoblot study.
  62. (1980). Effect of bile salts and related compounds on isolated oesophageal mucosa.
  63. (1994). Effect of gastroduodenal juice and dietary fat on the development of Barrett's esophagus and esophageal neoplasia: An experimental rat model. doi
  64. (1981). Effects of acid and bile salts on rabbit oesophgeal mucosa. doi
  65. (1999). Endoscopic ablation therapy for Barrett's esophagus with high-grade dysplasia: A reveiw. doi
  66. (1997). Epidemiology and molecular biology of Barrett's adenocarcinoma. doi
  67. (1997). Epidermiology of columnar lined esophagus and adenocarcinoma. doi
  68. (2000). Epidermiology of esophageal cancer, especially adenocarcinoma of the esophagus and esophagogastric junction. doi
  69. (1998). Epithelial cell proliferative activity of barrett's esophagus. Methodology and correlation with traditional cancer risk markers. doi
  70. (1997). Etiology of Barrett's metaplasia and esophageal adenocarcinoma.
  71. (1998). Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis. doi
  72. (1994). Expression of plasminogen activators and their inhibitors in oesophageal carcinoma. doi
  73. (1998). Expressiopn of beta-catenin, alphacatenin and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
  74. (1997). Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. doi
  75. (1997). Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. doi
  76. (1997). Gastroesophageal reflux disease in patients with columnar lined esophagus. doi
  77. (1998). Gastroesophageal reflux in infants and children. Mayo Clinics doi
  78. (1997). Gastroesophageal. reflux disease. doi
  79. (1998). Gatroesophageal reflux disease: Pathogenesis, symptoms and complications.
  80. (1986). Histological and histochemical changes in the columnar lined (Barret's ) oesophagus. doi
  81. (1996). How Cancer arises. doi
  82. (1997). Human Ageing and Telomeres, doi
  83. (1997). Human erythrocyte glucose transporter (Glutl) is immunohistochemically detected as a late event during malignant progression in Barrett's metaplasia.
  84. (1995). Human telomere loss, ageing and cancer,
  85. (1985). Human urokinase gene is located on the long arm of chromosome 10. doi
  86. (1999). Identification of intestinaltype Barrett's metaplasia by using the intestinal specific protein villin and esophageal brush cytology. doi
  87. (1994). Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. doi
  88. (1991). Immunolocation of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. doi
  89. (1998). Impact of enoscopic biopsy surveillance of Barrett's oesophagus: Pathological stage and clinical outcome of Barrett's carcinoma. doi
  90. (1994). Impact of urokinase-type plasminogen activator and its inhibitor type 1 in prognosis in cervical cancer of the uterus. doi
  91. (1998). In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. doi
  92. (1992). In vivo patterns of expression of urokinase and its inhibitor PAM suggest a concerted role in regulating physiological angiogenesis. doi
  93. (1993). Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. doi
  94. (1990). Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. doi
  95. (1994). Intestinal differentiation and p53 gene alterations in Barrett's esophagus and esophageal adenocarcinoma. doi
  96. (1999). Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system and inhibition by anti sense oligonucleotides to urokinase or urokinase receptor.
  97. (1997). Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus. doi
  98. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. doi
  99. (1995). Long term continuos omeprazole treatment of patients with Barrett's oesophagus. doi
  100. (1992). Loss of heterozygosity involves multiple tumour suppresser genes in human esophageal cancers.
  101. (2000). Malignant progression in Barrett's esophagus: Pathology and molecular biology. Recent Results in Cancer Research Naitoh doi
  102. (1990). Mechanisms of trophoblast invasiveness and their control: The role of proteases and protease inhibitors. doi
  103. (1996). Metaplastic columnar cells in Barrett's esophagus: A common and neglected cell type. doi
  104. (1994). Molecular Biology of the Cell, doi
  105. (1993). Molecular mechanisms of protease-mediated tumour invasiveness. doi
  106. (1983). Morphological alterations in experimental oesophagitis. doi
  107. (1997). Morphology of Barrett's esophagus and Barrett's associated dysplasia and adenocarcinoma. doi
  108. (1998). Multifunctional potential of the plasminogen activation system in tumour invasion and metastasis (Reveiw). doi
  109. (2001). neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein. doi
  110. (1999). Over expression of human telomerase RNA is an early event in oesophageal carcinogenesis. doi
  111. (1993). p53 protein accumulation in Barrett's metaplasia, dysplasia and carcinoma: a follow-up study. doi
  112. (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with trans activating death-inducing and dominant-negative activities. doi
  113. (2001). Pathogenesis of gastroesophageal reflux and Barrett's esophagus. Mayo Clinics doi
  114. (1906). Peptic ulcer of the oesophagus. doi
  115. (1999). Phd Thesis
  116. (1998). Photodynamic ablation of high grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. doi
  117. (1995). Plasminogen activator inhibitor type 2 inhibits tumour necrosis factor alpha-induced apoptosis: evidence for an alternative biological function. doi
  118. (1993). Plasminogen activator inhibitors in endometrial adenocarcinoma. doi
  119. (1991). Plasminogen activators in human gastric cancers: Correlation with DNA ploidy and immunohistochemical. staining. doi
  120. (1987). Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence. doi
  121. (1997). Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the oesophagus. doi
  122. (2000). Proteases in gastrointestinal neoplastic diseases. doi
  123. (1993). Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium.
  124. (1991). Rising incidence of adenocarcinoma of the esophagus and gastric cardia. doi
  125. (1999). Role of p53 assessment in management of Barrett's esophagus.
  126. (1995). Screening for Barrett's esophagus by balloon cytology.
  127. (1999). Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. doi
  128. (1997). Short segment Barrett's oesophagus: prevalence, diagnosis and associations. doi
  129. (1999). Significance of Fas and Retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. doi
  130. (1994). Specific association of human telomerase activity with immortal cells and cancer. doi
  131. (1997). Src activation in malignant and premalignant epithelia of Barrett's esophagus. doi
  132. (1998). Strong prognostic impact of tumour-associated urokinasetype plasminogen activator in completely resected adenocarcinoma of the esophagus.
  133. (1997). Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. doi
  134. (1976). Studies on the role of plasminogen activator in ovulation. doi
  135. (1993). Sucrase-isomaltase gene expression in Barrett's esophagus and adenocarcinoma.
  136. (1997). Surveillance of Patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. doi
  137. (1976). Telomerase activity and abnormal expression of p 16 and cyclin D1 in Barrett's esophagus. Gastrointestinal Oncology (abstract) 112: 635
  138. (1998). Telomerase activity and expression of its RNA component in cervial lesions.
  139. (1999). Telomerase activity and in situ telomerase RNA expression in oral carcinogenesis. doi
  140. (1996). Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma derived skin keratinocytes. doi
  141. (1996). Telomerase and cancer: Revisiting the telomere hypothesis. doi
  142. (1997). Telomerase and the chromosome end replication problem. doi
  143. (1997). Telomerase assays in the diagnosis and prognosis of cancer, doi
  144. (1995). Telomerase biochemistry and regulation, doi
  145. (1997). Telomerase in the early detection of cancer. doi
  146. (1999). Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions. doi
  147. (2000). Telomerase Reverse Transcriptase Expression is increased in the Barrett's Metaplsia, Dysplasia, Adenocarcinoma Sequence.
  148. (1995). Telomere dynamics and genome instability in human cancer,
  149. (1987). Telomere,
  150. (1982). The catalogue of human cytokeratins: Patterns of expression in normal epithelia, tumours and cultured cells. doi
  151. (1996). The columnar-lined esophagus, intestinal metaplasia and doi
  152. (1997). The limited reproductive life span of normal human cells in culture, doi
  153. (1963). The lower esophagus lined by columnar epithelium: Its association with hiatal hernia, ulcer, stricture and tumour. doi
  154. (1957). The lower oesophagus lined by columnar epithelium. doi
  155. (1997). The molecular basis for carcinogenesis in metaplastic columnar-lined esophagus. doi
  156. (1989). The oeophageal lining,
  157. (1953). The oesophagus lined with gastric mucous membrane. doi
  158. (1986). The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the sema cell type. doi
  159. (1987). The relationship between columnar epithelial dysplasia and invasive adenocarcinoma arising in Barrett's esophagus.
  160. (1995). The RNA component of human telomerase. doi
  161. (1972). The role of bile and acid in the production of oesophagitis and the motor defect of oesophagitis. doi
  162. (1997). The telomere and telomerase: How do they interact?, doi
  163. (1997). The urokinasetype plasminogen activator system in cancer metastasis: A review.
  164. (1999). Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity. doi
  165. (2002). Tumour invasion and metastases: Role of the basement membrane.
  166. (1992). Type-1 plasminogen activator inhibitor in human breast carcinomas. doi
  167. (2000). Unravelling the role of proteases in cancer. doi
  168. (1993). Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness. doi
  169. (1991). Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. doi
  170. (1993). Y chromosome loss in esophageal carcinoma: An in situ hybridization study. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.